Filtered By:
Source: Vaccine
Vaccination: Influenza Vaccine
This page shows you your search results in order of date.
Order by Relevance | Date
Total 687 results found since Jan 2013.
Review: Factors influencing parents' decisions to vaccinate children against COVID-19
CONCLUSION: This review identified critical factors affecting parents' vaccination behavior for their children. Awareness of these factors may reduce parents' COVID-19 vaccine refusal for their children and guide future planning and development of public health studies.PMID:37735055 | DOI:10.1016/j.vaccine.2023.09.020
Source: Vaccine - September 21, 2023 Category: Allergy & Immunology Authors: Haifa S Alharbi Source Type: research
Vaccine Effectiveness of non-adjuvanted and adjuvanted trivalent inactivated influenza vaccines in the prevention of influenza-related hospitalization in older adults: A pooled analysis from the Serious Outcomes Surveillance (SOS) Network of the Canadian Immunization Research Network (CIRN)
CONCLUSIONS: Adjusting for frailty, aTIV showed statistically significantly better protection than naTIV against influenza-associated hospitalizations in older adults. In future studies, it is important to consider frailty as a significant confounder of VE.PMID:37696717 | DOI:10.1016/j.vaccine.2023.08.070
Source: Vaccine - September 11, 2023 Category: Allergy & Immunology Authors: Henrique Pott Melissa K Andrew Zachary Shaffelburg Michaela K Nichols Lingyun Ye May ElSherif Todd F Hatchette Jason LeBlanc Ardith Ambrose Guy Boivin William Bowie Jennie Johnstone Kevin Katz Phillipe Lagac é-Wiens Mark Loeb Anne McCarthy Allison McGeer Source Type: research
A recombinant chimeric influenza virus vaccine expressing the consensus H3 hemagglutinin elicits broad hemagglutination inhibition antibodies against divergent swine H3N2 influenza viruses
This study focuses on the hemagglutinin (HA) consensus-based approach towards developing a more broadly protective swine influenza vaccine against various H3 strains circulating in domestic pig populations. By computationally analyzing >1000 swine H3 full-length HA sequences, we generated a consensus H3 and expressed it in the context of influenza A WSN/33 reverse genetics system. The derived recombinant chimeric swine influenza virus with the consensus H3 was inactivated and further evaluated as a potential universal vaccine in pigs. The consensus H3 vaccine elicited broadly active hemagglutination inhibition (HI) anti...
Source: Vaccine - September 9, 2023 Category: Allergy & Immunology Authors: Jieshi Yu Chithra Sreenivasan Zhizhang Sheng Shao-Lun Zhai Jared W Wollman Sisi Luo Chen Huang Rongyuan Gao Zhao Wang Radhey S Kaushik Jane Christopher-Hennings Eric Nelson Ben M Hause Feng Li Dan Wang Source Type: research
Vaccination acceptability in the French general population and related determinants, 2000-2021
This study describes the evolution of vaccination acceptability and associated determinants in the French general population between 2000 and 2021, and vaccinations with the highest vaccine hesitancy between 2010 and 2021.METHODS: Data were collected from the nine national 'Health Barometer' cross-sectional surveys conducted between 2000 and 2021. These surveys included French-speaking individuals aged 18-75 years old who were selected through randomly generated landline and mobile phone numbers. Participants were asked about their acceptability of vaccination in general and their vaccine hesitancy toward any particular va...
Source: Vaccine - September 6, 2023 Category: Allergy & Immunology Authors: Sophie Vaux Arnaud Gautier Oriane Nassany Isabelle Bonmarin Source Type: research
A systematic review of barriers and enablers associated with uptake of influenza vaccine among care home staff
CONCLUSION: Interventions aimed at increasing influenza vaccine uptake among CH staff should focus on addressing the barriers identified in this review. These interventions should include components such as enhancing knowledge by providing accurate information about vaccine benefits and safety, addressing negative beliefs by challenging misconceptions, managing concerns and fears through open communication, and improving accessibility to the vaccine through convenient on-site options. This review provides a foundation for the development of tailored Interventions to improve influenza vaccine uptake among CH staff.PMID:3767...
Source: Vaccine - September 6, 2023 Category: Allergy & Immunology Authors: Faisal Alsaif Michael Twigg Sion Scott Annie Blyth David Wright Amrish Patel Source Type: research
Vaccination acceptability in the French general population and related determinants, 2000-2021
This study describes the evolution of vaccination acceptability and associated determinants in the French general population between 2000 and 2021, and vaccinations with the highest vaccine hesitancy between 2010 and 2021.METHODS: Data were collected from the nine national 'Health Barometer' cross-sectional surveys conducted between 2000 and 2021. These surveys included French-speaking individuals aged 18-75 years old who were selected through randomly generated landline and mobile phone numbers. Participants were asked about their acceptability of vaccination in general and their vaccine hesitancy toward any particular va...
Source: Vaccine - September 6, 2023 Category: Allergy & Immunology Authors: Sophie Vaux Arnaud Gautier Oriane Nassany Isabelle Bonmarin Source Type: research
A systematic review of barriers and enablers associated with uptake of influenza vaccine among care home staff
CONCLUSION: Interventions aimed at increasing influenza vaccine uptake among CH staff should focus on addressing the barriers identified in this review. These interventions should include components such as enhancing knowledge by providing accurate information about vaccine benefits and safety, addressing negative beliefs by challenging misconceptions, managing concerns and fears through open communication, and improving accessibility to the vaccine through convenient on-site options. This review provides a foundation for the development of tailored Interventions to improve influenza vaccine uptake among CH staff.PMID:3767...
Source: Vaccine - September 6, 2023 Category: Allergy & Immunology Authors: Faisal Alsaif Michael Twigg Sion Scott Annie Blyth David Wright Amrish Patel Source Type: research
Developmental and reproductive safety of Advax-CpG55.2 ™ adjuvanted COVID-19 and influenza vaccines in mice
Vaccine. 2023 Aug 31:S0264-410X(23)01007-1. doi: 10.1016/j.vaccine.2023.08.053. Online ahead of print.ABSTRACTSpikoGen® is a recombinant spike protein vaccine against COVID-19 that obtained marketing authorization in the Middle East on October 6th, 2021, becoming the first adjuvanted protein-based COVID-19 vaccine of its type to achieve approval. SpikoGen® vaccine utilizes a unique adjuvant Advax-CpG55.2, which comprises delta inulin and CpG55.2 oligonucleotide, a synthetic human toll-like receptor (TLR)-9 agonist. As part of a safety assessment, developmental and reproductive toxicity (DART) studies were undertaken in m...
Source: Vaccine - September 2, 2023 Category: Allergy & Immunology Authors: Isaac G Sakala Yoshikazu Honda-Okubo Nikolai Petrovsky Source Type: research
The potential cost-effectiveness of next generation influenza vaccines in England and Wales: A modelling analysis
Vaccine. 2023 Aug 24:S0264-410X(23)00963-5. doi: 10.1016/j.vaccine.2023.08.031. Online ahead of print.ABSTRACTNext generation influenza vaccines are in development and have the potential for widespread health and economic benefits. Determining the potential health and economic impact for these vaccines is needed to drive investment in bringing these vaccines to the market, and to inform which groups public health policies on influenza vaccination should target. We used a mathematical modelling approach to estimate the epidemiological impact and cost-effectiveness of next generation influenza vaccines in England and Wales. ...
Source: Vaccine - August 26, 2023 Category: Allergy & Immunology Authors: Naomi R Waterlow Simon R Procter Edwin van Leeuwen Sreejith Radhakrishnan Mark Jit Rosalind M Eggo Source Type: research
Predictors of immune persistence induced by two-dose BBIBP-CorV vaccine in high-risk occupational population
CONCLUSIONS: From 28 days to 10 months after receipt of the second dose of the BBIBP-CorV vaccine, neutralizing antibody levels were substantially decreased, especially among men, among persons 50 years of age or older, among persons with the 0-14 d group, and among persons without history of influenza vaccination.TRIAL REGISTRATION: Chinese Clinical Trial Registry, ChiCTR2100041705, ChiCTR2100041706.PMID:37604725 | DOI:10.1016/j.vaccine.2023.08.042
Source: Vaccine - August 21, 2023 Category: Allergy & Immunology Authors: Tian Yao Yana Guo Xiuyang Xu Xiaohong Zhang Shengcai Mu Junfeng Huo Zhiyun Wei Ling Liu Xiaoqing Li Hong Li Rongqin Xing Yongliang Feng Jing Chen Lizhong Feng Suping Wang Source Type: research
Influenza vaccine effectiveness against influenza A during the delayed 2022/23 epidemic in Shihezi, China
Vaccine. 2023 Aug 19:S0264-410X(23)00971-4. doi: 10.1016/j.vaccine.2023.08.039. Online ahead of print.ABSTRACTAfter the temporary end of COVID-19 in China in February 2023, the influenza epidemic peaked in March across many Chinese places. We recruited a total of 258 all-age subjects presenting influenza-like illness (ILI) in Shihezi city, China from January 1 to March 16, 2023, and tested for influenza virus infection. Using a test-negative design, we assessed influenza vaccine effectiveness (VE) of 56.3% (95% CrI: 13.6, 73.6) against medically attended, influenza illness during the delayed 2022/23 influenza epidemic. The...
Source: Vaccine - August 21, 2023 Category: Allergy & Immunology Authors: Yinxia Su Zihao Guo Xiu Gu Shengzhi Sun Kai Wang Songsong Xie Shi Zhao Source Type: research
Predictors of immune persistence induced by two-dose BBIBP-CorV vaccine in high-risk occupational population
CONCLUSIONS: From 28 days to 10 months after receipt of the second dose of the BBIBP-CorV vaccine, neutralizing antibody levels were substantially decreased, especially among men, among persons 50 years of age or older, among persons with the 0-14 d group, and among persons without history of influenza vaccination.TRIAL REGISTRATION: Chinese Clinical Trial Registry, ChiCTR2100041705, ChiCTR2100041706.PMID:37604725 | DOI:10.1016/j.vaccine.2023.08.042
Source: Vaccine - August 21, 2023 Category: Allergy & Immunology Authors: Tian Yao Yana Guo Xiuyang Xu Xiaohong Zhang Shengcai Mu Junfeng Huo Zhiyun Wei Ling Liu Xiaoqing Li Hong Li Rongqin Xing Yongliang Feng Jing Chen Lizhong Feng Suping Wang Source Type: research
Influenza vaccine effectiveness against influenza A during the delayed 2022/23 epidemic in Shihezi, China
Vaccine. 2023 Aug 19:S0264-410X(23)00971-4. doi: 10.1016/j.vaccine.2023.08.039. Online ahead of print.ABSTRACTAfter the temporary end of COVID-19 in China in February 2023, the influenza epidemic peaked in March across many Chinese places. We recruited a total of 258 all-age subjects presenting influenza-like illness (ILI) in Shihezi city, China from January 1 to March 16, 2023, and tested for influenza virus infection. Using a test-negative design, we assessed influenza vaccine effectiveness (VE) of 56.3% (95% CrI: 13.6, 73.6) against medically attended, influenza illness during the delayed 2022/23 influenza epidemic. The...
Source: Vaccine - August 21, 2023 Category: Allergy & Immunology Authors: Yinxia Su Zihao Guo Xiu Gu Shengzhi Sun Kai Wang Songsong Xie Shi Zhao Source Type: research
